Stockreport

Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density

Atossa Therapeutics, Inc.  (ATOS) 
Last atossa therapeutics, inc. earnings: 11/13 04:10 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.atossagenetics.com
PDF 1 MG Dose (Z)-Endoxifen Shows Potential as a Well-Tolerated, Preventative Therapy for Premenopausal Women at Risk of Developing Breast Cancer Data to be Presented in a [Read more]